Browse by Medical Category
Friday, April 19, 2019 Mass General
Friday, April 14, 2017 Mass General
Tuesday, August 2, 2016 Mass General
Friday, April 15, 2016 Mass General
Tuesday, July 15, 2014 Mass General
Tuesday, July 16, 2013 Mass General
Friday, May 24, 2013 Mass General
Friday, November 9, 2012 Mass General
Friday, September 28, 2012 Mass General
Friday, May 25, 2012 Mass General
Friday, December 2, 2011 Mass General
Friday, May 6, 2011 Research
Friday, April 22, 2011 Mass General
Friday, January 28, 2011 Mass General
Friday, January 14, 2011 Mass General
Friday, October 15, 2010 Mass General
Friday, September 3, 2010 Mass General
Friday, May 15, 2009 Research
Featuring Dr. John Iafrate of MGH Pathology
Featuring Dr. Luca Pinello of MGH Pathology
Featuring Dr. David Langenau of MGH Pathology
Featuring Dr. Keith Joung of MGH Pathology
Dr. Bernstein, Dr. Getz and Dr. Joung have made the Thomson Reuters 2016 Highly Cited Researchers list!
Drs. Gilbertson, Wilbur and Louis explain how digital pathology is impacting diagnosis and treatment.
Dr. Bernstein's work with DNA packaging has been mentioned in National Institutes of Health Director's Blog; Creative Minds: A New Way to Look at Cancer
Check out Dr. Suva’s Advances at Mass General Cancer Center podcast, which discusses the topic “Identifying Therapeutic Targets for IDH-Mutant Brain Tumors"
CRISPR-Cas genome-editing nucleases hold substantial promise for developing human therapeutic applications1-6 but identifying unwanted off-target mutations is important for clinical translation7. A well-validated method that can reliably identify off-targets in vivo has not been described to date, which means it is currently unclear whether and how frequently these mutations occur. Here we describe 'verification of in vivo off-targets' (VIVO), a highly sensitive strategy that can robustly identify the genome-wide off-target effects of CRISPR-Cas nucleases in vivo. We use VIVO and a guide RNA deliberately designed to be promiscuous to show that CRISPR-Cas nucleases can induce substantial off-target mutations in mouse livers in vivo.
The TP53 tumor-suppressor gene is mutated in >50% of human tumors and Li-Fraumeni patients with germ line inactivation are predisposed to developing cancer. Here, we generated tp53 deleted zebrafish that spontaneously develop malignant peripheral nerve-sheath tumors, angiosarcomas, germ cell tumors, and an aggressive Natural Killer cell-like leukemia for which no animal model has been developed.
The International Collaboration on Cancer Reporting has published its first datasets on central nervous system tumors. These provide guidelines and detailed background information relating to diagnostic pathology reporting and are intended to influence practice around the world. Development of the central nervous system tumor datasets was directed by Dr. David Louis, chair of MGH Pathology.
See quotes from Chief David Louis on Mass General and Brigham and Women’s launch of their combined digital pathology project with Royal Philips
An accurate, scalable approach for monitoring cancer DNA from blood samples has been developed by researchers at the Broad Institute of MIT and Harvard, Koch Institute at MIT, Dana-Farber Cancer Institute, and Massachusetts General Hospital.
Catch up on Dr. Langenau's article discussing Protein identified that drives initiation and growth of aggressive form of leukemia.
Dr. Langenau discusses dissecting hematopoietic and renal cell heterogeneity in adult zebrafish at single-cell resolution using RNA sequencing.
Dr. Rivera explores cancer-specific retargeting of BAF complexes by a prion-like domain.
Dr. Rivera's article about Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain.
Dr. Joung discusses a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets.
Check out Dr. Langenau's article on growth and self-renewal in embryonal rhabdomyosarcoma.
Since 1811, people have counted on Mass General for answers, innovations and medical leadership. As our third century dawns, we remain ready to serve.
A new animal model developed by Massachusetts General Hospital investigators promises to be less expensive, easier to use and to improve personalized therapies for cancers and potentially other diseases.
A Massachusetts General Hospital research team reports that several of the recently developed CRISPR base editors, which create targeted changes in a single DNA base, can induce widespread off-target effects in RNA, extending beyond the targeted DNA.
A research team led by Massachusetts General Hospital investigators has assembled a detailed atlas of bone marrow cells from patients with acute myeloid leukemia, an aggressive blood cancer that usually leads to death within five years of diagnosis.
Mass. General-led study reveals cell types relevant to disease progression, immune response suppression
A multi-institutional research team, led by investigators at Massachusetts General Hospital and the Broad Institute of MIT and Harvard, has identified specific states of cytotoxic CD8 T cells that are associated with patient response to checkpoint immunotherapy for melanoma.
A team of Massachusetts General Hospital Cancer Center researchers has determined one way that mutations in a gene involved in a rare, hereditary cancer syndrome lead to out-of-control cellular proliferation.
A Massachusetts General Hospital research team has used epigenome editing tools to investigate how the genetic abnormality that drives Ewing sarcoma – the second most common bone cancer in children and young adults – unleashes tumor growth.
A new approach to analyzing prostate gland tissue developed by Massachusetts General Hospital researchers may help address a major challenge in treating prostate cancer – determining which tumors are unlikely to progress and which could be life threatening and require treatment.
Head and neck tumors that contain cells undergoing a partial epithelial-to-mesenchymal transition — which transforms them from neatly organized blocks into irregular structures that extrude into the surrounding environment — are more likely to invade and spread to other parts of the body, according to a new study led by researchers from Mass. Eye and Ear, Massachusetts General Hospital and the Broad Institute of MIT and Harvard
A team led by Massachusetts General Hospital investigators has identified a new cancer-causing pathway behind most cases of an aggressive type of leukemia, findings that could lead to new targeted treatment approaches.
A Massachusetts General Hospital (MGH)-based research team is one of seven nationwide receiving contracts under the DARPA Safe Genes program, which is designed to improve the safety of gene drives.
Detailed analysis of two brain tumor subtypes has revealed that they may originate from the same type of neural progenitor cells and be distinguished by gene mutation patterns and by the composition of their microenvironments.
A study from investigators at Massachusetts General Hospital finds that a blood transfusion practice previously studied only in patients with severe traumatic injuries has been widely adopted within the hospital for surgical patients without traumatic injuries, for whom it may not be beneficial.
Massachusetts General Hospital researchers have identified a mechanism that controls the expression of genes regulating the growth of the most aggressive form of medulloblastoma, the most common pediatric brain tumor.
– A study analyzing brain tumor genomics on a single-cell level has found evidence that cancer stem cells fuel the growth of oligodendrogliomas, a slow-growing but incurable form of brain cancer.
Combining optical coherence tomography with another advanced imaging technology may more accurately identify coronary artery plaques that are most likely to rupture and cause a heart attack.
Over the past decade, studies have found that obesity and eating a high-fat, high-calorie diet are significant risk factors for many types of cancer. Now, a new study reveals how a high-fat diet makes the cells of the intestinal lining more likely to become cancerous.
The Foundation for the National Institutes of Health has selected Jeannie T. Lee, M.D., Ph.D., as the 2016 winner of the Lurie Prize in Biomedical Sciences for uncovering the functions of long, noncoding RNA in epigenetic regulation.
A new engineered version of the gene-editing CRISPR-Cas9 nuclease appears to robustly abolish the unwanted, off-target DNA breaks that are a significant current limitation of the technology, reducing them to undetectable levels.
In a landmark study, researchers from the Broad Institute and MGH reveal a completely new biological mechanism that underlies cancer.
A method developed by MGH investigators to improve the usefulness and precision of the most common form of the gene-editing tools CRISPR-Cas9 RNA-guided nucleases can be applied to Cas9 enzymes from other bacterial sources, allowing targeting of genomic sites previously inaccessible to CRISPR-Cas9 technology.
Massachusetts General Hospital Department of Pathology and Cancer Center investigator Bradley Bernstein, MD, PhD, is one of three recipients of the 2015 Paul Marks Prize for Cancer Research, given by the Memorial Sloan-Kettering Cancer Center. Bernstein is being honored for his investigations into how the structural organization or ‘packaging’ of our DNA within cells influences the functions of our genes.
A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today’s most significant challenges in genomic medicine – determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
A team of Massachusetts General Hospital MGH researchers has found a way to expand the use and precision of the powerful gene-editing tools called CRISPR-Cas9 RNA-guided nucleases.
MGH investigators have found the probable mechanism underlying a previously described biomarker associated with the risk of developing serious diseases ranging from cancer to cardiovascular disease and the risk of serious complications.
Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Boston University School of Medicine (BUSM) have identified the first potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate.
Massachusetts General Hospital investigators have developed a method of detecting, across the entire genome of human cells, unwanted DNA breaks induced by use of the popular gene-editing tools called CRISPR-Cas RNA-guided nucleases.
The genetic abnormality that drives the bone cancer Ewing sarcoma operates through two distinct processes – both activating genes that stimulate tumor growth and suppressing those that should keep cancer from developing.
A novel partnership between Massachusetts General Hospital and Massachusetts Institute of Technology is addressing three major challenges in clinical medicine – improving the diagnosis of disease, developing new approaches to prevent and treat infectious and autoimmune diseases, and developing more accurate methods of diagnosing and treating major neurodegenerative and psychiatric diseases.
A next-generation genome editing system developed by MGH investigators substantially decreases the risk of producing unwanted, off-target gene mutations.
A simple assay developed by an MGH research team can reveal the evolutionary relationships among various tumor sites within a patient, information that may someday help with treatment planning.
The activity of four transcription factors appears to distinguish the small proportion of glioblastoma cells responsible for the aggressiveness and treatment resistance of the deadly brain tumor. The findings identify molecular circuits that may be targeted by new therapeutic approaches
MGH investigators have found that adjusting the length of the the guide RNA component of the gene-editing tools called CRISPR-Cas RNA-guided nucleases can substantially reduce the occurrence of DNA mutations at off-target sites.
A comparison of three methods of predicting recurrence risk in women treated for estrogen-receptor-positive breast cancer finds that only the breast cancer index – a biomarker based on the expression levels of seven tumor-specific genes – accurately identifies patients who continue to be at risk after five years of estrogen-blocking treatment.
A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment.
MGH researchers have found a significant limitation to the use of a new gene-editing tool called CRISPR-Cas RGNs, production of unwanted DNA mutations at sites other than the desired target. Their findings indicate the need to improve the precision of the technology.
A team led by MGH researchers has identified a genetic signature that may reflect the risk of tumor recurrence or spread in men surgically treated for prostate cancer. If confirmed, the genetic risk index also may help distinguish tumors that require aggressive treatment from those that can safely be monitored.
Researchers at the Wellman Center for Photomedicine at Massachusetts General Hospital have developed an imaging system enclosed in a capsule about the size of a multivitamin pill that creates detailed, microscopic images of the esophageal wall.
Massachusetts General Hospital has moved into the number one spot on the 2012-13 U.S. News & World Report’s “America’s Best Hospitals” list.
A study from Massachusetts General Hospital researchers suggests that specific populations of tumor cells have different roles in the process by which tumors make new copies of themselves and grow.
Development of a new way to make a powerful tool for altering gene sequences should greatly increase the ability of researchers to knock out or otherwise alter the expression of any gene they are studying.
MGH Cancer Center investigators have defined the role of a recently identified gene abnormality – rearrangements in the ROS1 gene – in non-small-cell lung cancer, the leading cause of cancer death in the U.S. They also show that these tumors can be treated with crizotinib and describe the remarkable response of one patient to such treatment.
Investigators at the MGH Cancer Center have identified a new genetic signature associated with bile duct cancer, a usually deadly tumor for which effective treatment currently is limited.
A small percentage of the deadly brain tumors called glioblastomas, which usually resist treatment with drugs targeting mutations in cell-growth genes, appears to contain extra copies of two or three of these genes at the same time. The surprising discovery has major implications for the understanding of tumor biology and for targeted cancer therapies.
A new device that combines two microimaging technologies can reveal both the detailed anatomy of arterial linings and biological activities that, in coronary arteries, could indicate the risk of heart attacks or the formation of clots in arterial stents.
Researchers at the Wellman Center for Photomedicine at MGH have developed a one-micrometer-resolution version of the intravascular imaging technology optical coherence tomography that can reveal cellular and subcellular features of coronary artery disease.
Genes make up only a tiny percentage of the human genome, but the rest may hold vital clues about the genetic origins of disease. Using a new mapping strategy, a research team has begun to assign meaning to the regions beyond our genes and has revealed how minute changes in these regions might be connected to common diseases.
A team led by MGH researchers has developed a faster way to engineer synthetic enzymes that target specific DNA sequences for inactivation, repair or alteration.
An MGH physician-researcher and a Harvard University mathematician have collaborated to develop a mathematical model reflecting how red blood cells change during their four-month lifespan. The model uses data from routine blood tests and may be able to predict the development of anemia.
A protein known to be involved in a rare hereditary cancer syndrome may have a role in the regulation of liver stem cells and the development of liver cancer.
A detailed analysis of the epigenetics – factors controlling when and where genes are expressed – of Wilms tumor reveals striking similarities to stem cells normally found in fetal kidneys. These findings by MGH Cancer Center researchers reveal new cellular pathways critical for Wilms tumor development that may apply to other pediatric cancers.
Magnetic resonance spectroscopy – which analyzes the biochemistry rather than the structure of tissues – may someday be able both to pinpoint the precise location of prostate cancer and to determine the tumor's aggressiveness, information that could help guide treatment planning.
Two MGH investigators – Bradley E. Bernstein, MD, PhD, and Konrad Hochedlinger, PhD – are among 50 receipients of the Howard Hughes Medical Institute Early Career Scientist Awards.
Back to Top